Acantholytic Pityriasis Rubra Pilaris Associated with Imiquimod 3.75% Application
Imiquimod is an immunomodulator with both antitumor and antiviral properties. It is currently available in two cream formulations as Aldara (imiquimod 5%) and the newly approved Zyclara (imiquimod 3.75%). Imiquimod has been associated with localized erythema, crusting, and scaling at the site of app...
Saved in:
| Main Authors: | Natasha Atanaskova Mesinkovska, Danyelle Dawes, Apra Sood, Wilma Bergfeld |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Case Reports in Dermatological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2011/412684 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug-related pityriasis rubra pilaris with acantholysis
by: Gajinov Zorica T., et al.
Published: (2013-01-01) -
A case of pityriasis rubra pilaris secondary to ponatinib
by: Ariana Nateghi, et al.
Published: (2025-01-01) -
A Review of Pityriasis Rubra Pilaris and Rheumatologic Associations
by: Happy Chan, et al.
Published: (2004-01-01) -
Sorafenib-Induced Pityriasis Rubra Pilaris-like Eruption: A Case Report
by: Tejasvi Patel, et al.
Published: (2025-07-01) -
Efficacy of Bimekizumab in the Management of Refractory Erythrodermic Pityriasis Rubra Pilaris: Clinical Insights
by: Sofia Theotokoglou, et al.
Published: (2025-07-01)